In particular, the third generation anti-EGFR osimertinib is currently recommended for patients with EGFR-mutated lung adenocarcinoma, alectinib, or brigatinib for those harboring ALK rearrangements, and crizotinib for those with ROS1 rearrangement. Here, ALK is linked to lung adenocarcinoma.